What's new in the pathophysiology of Parkinson's disease? • 2024 MDS Congress

Dr. Andrew Siderowf, Hertig Stern Professor of Neurology at the University of Pennsylvania, dives into the evolving landscape of Parkinson's disease research. He discusses the prominence of alpha-synuclein biomarkers and their implications for diagnosis and treatment. The conversation highlights innovative methods like skin-based assays and imaging biomarkers. Siderowf also explores the future of treatment, including the impact of artificial intelligence on therapeutic strategies and the complexity of the disease beyond synuclein pathology.